Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27377923.
- Also identified by DOI 10.1093/jnci/djw133 and PMC identifier 6279296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide; its incidence is increasing in the United States. Depending on disease extent and underlying liver status, patients may be treated with local, locoregional, and/or systemic therapy. Recent data indicates that radiotherapy (RT) can play a meaningful role in the management of HCC. Here, we review published experiences using RT for HCC, including the use of radiosensitizers and stereotactic RT. We discuss methods for performing preclinical studies of RT for HCC and biomarkers of response. As a part of the HCC Working Group, an informal committee of the National Cancer Institute's Radiation Research Program, we suggest how RT should be implemented in the management of HCC and identify future directions for the study of RT in HCC.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Radiation-Sensitizing Agents